# Identifier: Patient identifier					
# Group.Number: Numeric code for the group to which the sample belongs					
# AML.Subgroup: Name of the group to which the sample belongs					
# ShortGroupName: Abbreviation of te group name					
# FileName: Sample identifier; there may be multiple samples per patient					
Identifier	Group.Number	AML.Subgroup	ShortGroupName	FileName	
AML10	AML10	1	CBF-AML	CBF	AML10
AML8_x1	AML8	6	Normal Karotype AML FLT3 tyrosine kinase domain mutation	NK-FLT3-TKD	AML8_x1
Nl-1	Nl-1	10	Normal	Normal	Nl-1
Nl-3_x1	Nl-3	10	Normal	Normal	Nl-3_x1
Nl-5_x1	Nl-5	10	Normal	Normal	Nl-5_x1
Nl-6	Nl-6	10	Normal	Normal	Nl-6
AML19	AML19	5	Adverse-risk	ARK	AML19
AML20	AML20	3	NK-AML FLT3-ITD	NK-FLT3-ITD	AML20
AML21	AML21	3	NK-AML FLT3-ITD	NK-FLT3-ITD	AML21
AML22	AML22	8	MLL rearrangement	MLL	AML22
AML23	AML23	3	NK-AML FLT3-ITD	NK-FLT3-ITD	AML23
AML12	AML12	7	Granulylocytic sarcoma	GSARC	AML12
APL4	APL4	2	APL	APL	APL4
AML29	AML29	5	Adverse-risk	ARK	AML29
AML30	AML30	3	NK-AML FLT3-ITD	NK-FLT3-ITD	AML30
AML31	AML31	6	Normal Karotype AML FLT3 tyrosine kinase domain mutation	NK-FLT3-TKD	AML31
AML32	AML32	1	CBF-AML	CBF	AML32
AML33	AML33	4	NK-AML FLT3wt	NK-FLT3-wt	AML33
AML39	AML39	3	NK-AML FLT3-ITD	NK-FLT3-ITD	AML39
Nl-3_x2	Nl-3	10	Normal	Normal	Nl-3_x2
Nl-4_x2	Nl-4	10	Normal	Normal	Nl-4_x2
NL-6_x2	NL-6	10	Normal	Normal	NL-6_x2
AML13	AML13	4	NK-AML FLT3wt	NK-FLT3-wt	AML13
AML41	AML41	5	Adverse-risk	ARK	AML41
APL5	APL5	2	APL	APL	APL5
AML35	AML35	1	CBF-AML	CBF	AML35
AML36	AML36	4	NK-AML FLT3wt	NK-FLT3-wt	AML36
AML4	AML4	5	Adverse-risk	ARK	AML4
AML5	AML5	1	CBF-AML	CBF	AML5
AML6	AML6	6	Normal Karotype AML FLT3 tyrosine kinase domain mutation	NK-FLT3-TKD	AML6
AML7	AML7	3	NK-AML FLT3-ITD	NK-FLT3-ITD	AML7
AML9	AML9	3	NK-AML FLT3-ITD	NK-FLT3-ITD	AML9
APL3	APL3	2	APL	APL	APL3
CR6	CR6	9	Complete Recovery	CR	CR6
Nl-4_x3	Nl-4	10	Normal	Normal	Nl-4_x3
Nl-5_x3	Nl-5	10	Normal	Normal	Nl-5_x3
NL-6_x3	NL-6	10	Normal	Normal	NL-6_x3
CR3	CR3	9	Complete Recovery	CR	CR3
CR5	CR5	9	Complete Recovery	CR	CR5
AML14	AML14	4	NK-AML FLT3wt	NK-FLT3-wt	AML14
AML15	AML15	4	NK-AML FLT3wt	NK-FLT3-wt	AML15
CR7_x4	CR7	9	Complete Recovery	CR	CR7_x4
AML25_x4	AML25	5	Adverse-risk	ARK	AML25_x4
AML37	AML37	3	NK-AML FLT3-ITD	NK-FLT3-ITD	AML37
CR7_x1	CR7	9	Complete Recovery	CR	CR7_x1
AML38	AML38	3	NK-AML FLT3-ITD	NK-FLT3-ITD	AML38
AML8_x4	AML8	6	Normal Karotype AML FLT3 tyrosine kinase domain mutation	NK-FLT3-TKD	AML8_x4
APL1	APL1	2	APL	APL	APL1
Nl-3_x4	Nl-3	10	Normal	Normal	Nl-3_x4
Nl-4_x4	Nl-4	10	Normal	Normal	Nl-4_x4
Nl-5_x4	Nl-5	10	Normal	Normal	Nl-5_x4
NL-6_x4	NL-6	10	Normal	Normal	NL-6_x4
AML40	AML40	3	NK-AML FLT3-ITD	NK-FLT3-ITD	AML40
CR2	CR2	9	Complete Recovery	CR	CR2
AML18	AML18	5	Adverse-risk	ARK	AML18
AML25_x1	AML25	5	Adverse-risk	ARK	AML25_x1
AML26	AML26	1	CBF-AML	CBF	AML26
AML27	AML27	3	NK-AML FLT3-ITD	NK-FLT3-ITD	AML27
